Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL
Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL
复制标题
DOI：
10.1182/blood-2002-05-1352
复制
发表时间：
2004-01-01
期刊：
影响因子：
20.3
通讯作者：
Kikuchi, M
中科院分区：
文献类型：
--
作者：
Tsuchiya, T;Ohshima, K;Kikuchi, M
世界卫生组织最近提出了一个新的分类。然而，外周T细胞淋巴瘤的分类。仍有待澄清。特别是，未指明类型被认为是一个异质性的类别。本文研究了185例淋巴结T细胞淋巴瘤患者外周血中趋化因子受体、Th 1相关CXCR 3和CCR 5、Th 2相关标志物ST 2（L）、活化T细胞受体OX 40/CD 134的表达及其与预后的关系。它们的表达模式与淋巴结T细胞淋巴瘤的特定亚型相关，如血管免疫母细胞性T细胞淋巴瘤（AILD）、间变性大细胞淋巴瘤（ALCL），以及外周T细胞淋巴瘤（PTCL）中未指明的亚型。在AILD中，几乎所有的病例均为OX 40/CD 134（96%）和CXCR 3（89%）免疫反应阳性。在ALCL中，所有病例OX 40/CD 134免疫阴性，只有少数病例（24%）CXCR 3免疫阳性，而几乎所有病例（94%）ST 2（L）阳性。未指明的PTCL病例分为2组;第1组（ST 2（L）、CCR 5或CXCR 3阳性病例）与第2组（ST 2（L）、CCR 5和CXCR 3阴性病例）相比，倾向于显示良好的预后。我们的研究结果表明，进一步分型的PTCL，未指明，到组1和2可能是重要的评估预后和了解这些肿瘤的功能作用。
A new World Health Organization classification was recently proposed. However, classification of peripheral T-cell lymphomas. remains to be clarified. Particularly, unspecified type was considered as a heterogeneous category. Here we studied the expressions of chemokine receptors, Th1-associated CXCR3 and CCR5 and Th2-associated marker ST2(L), and activated T-cell receptor OX40/CD134 in 185 patients with nodal T-cell lymphoma, and evaluated the relationship to prognosis. Their expression patterns correlated with the specific subtype of nodal T-cell lymphoma, such as angioimmunoblastic T-cell lymphoma (AILD), anaplastic large cell lymphoma (ALCL), and, in peripheral T-cell lymphoma (PTCL), unspecified. In AILD, almost all cases were immunoreactive for OX40/CD134 (96%) and for CXCR3 (89%). In ALCL, all cases were immunonegative for OX40/CD134, and only a few cases (24%) were immunoreactive for CXCR3, whereas almost all cases (94%) were positive for ST2(L). Cases of PTCL, unspecified, were divided into 2 groups; group 1 (cases positive for either ST2(L), CCR5, or CXCR3) tended to show favorable prognosis compared with group 2 (cases negative for ST2(L), CCR5, and CXCR3). Our results indicate that further subtyping of PTCL, unspecified, into groups 1 and 2 could be significant for evaluating prognosis and understanding the functional role of these tumors.